Fintel reports that on October 10, 2023, Piper Sandler upgraded their outlook for Exact Sciences (NASDAQ:EXAS) from Neutral to Overweight .
Analyst Price Forecast Suggests 75.22% Upside
As of October 5, 2023, the average one-year price target for Exact Sciences is 112.95. The forecasts range from a low of 85.85 to a high of $136.50. The average price target represents an increase of 75.22% from its latest reported closing price of 64.46.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Exact Sciences is 2,322MM, an increase of 0.93%. The projected annual non-GAAP EPS is -2.69.
What is the Fund Sentiment?
There are 1206 funds or institutions reporting positions in Exact Sciences. This is an increase of 108 owner(s) or 9.84% in the last quarter. Average portfolio weight of all funds dedicated to EXAS is 0.37%, an increase of 26.78%. Total shares owned by institutions decreased in the last three months by 0.20% to 206,900K shares. 
The put/call ratio of EXAS is 0.78, indicating a bullish outlook.
What are Other Shareholders Doing?
Jpmorgan Chase holds 14,999K shares representing 8.30% ownership of the company. In it's prior filing, the firm reported owning 13,951K shares, representing an increase of 6.99%. The firm increased its portfolio allocation in EXAS by 957.62% over the last quarter.
Wellington Management Group Llp holds 10,803K shares representing 5.98% ownership of the company. In it's prior filing, the firm reported owning 10,837K shares, representing a decrease of 0.32%. The firm increased its portfolio allocation in EXAS by 31.73% over the last quarter.
ARK Investment Management holds 7,155K shares representing 3.96% ownership of the company. In it's prior filing, the firm reported owning 11,379K shares, representing a decrease of 59.04%. The firm decreased its portfolio allocation in EXAS by 16.12% over the last quarter.
Capital World Investors holds 6,798K shares representing 3.76% ownership of the company. In it's prior filing, the firm reported owning 6,625K shares, representing an increase of 2.55%. The firm increased its portfolio allocation in EXAS by 32.22% over the last quarter.
SEEGX - JPMorgan Large Cap Growth Fund Class I holds 6,662K shares representing 3.69% ownership of the company. In it's prior filing, the firm reported owning 5,712K shares, representing an increase of 14.27%. The firm increased its portfolio allocation in EXAS by 26.11% over the last quarter.
Exact Sciences Background Information
(This description is provided by the company.)
A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Exact Sciences unites visionary collaborators to help advance the fight against cancer.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
